

Revance Therapeutics, Inc.
Form 8-K
July 02, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 2, 2015

REVANCE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

DELAWARE (State of incorporation)	001-36297 (Commission File No.)	75-0551645 (IRS Employer Identification No.)
Revance Therapeutics, Inc. 7555 Gateway Boulevard Newark, California 94560 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (510) 742-3400		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
ITEM 5.02 APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS.

Jacob Waugh, M.D. will relinquish his role as Chief Scientific Officer of Revance Therapeutics, Inc. (the “Company”), effective July 2, 2015, and consult on key programs while serving as an advisor to the CEO and the Science and Technology Committee of the Company’s Board of Directors. As part of this change, Dr. Waugh will receive the equivalent of seven months of his base salary and a one-time payment of \$86,850, representing 50% of his target bonus opportunity for 2015 performance. As an advisor to the Company, Dr. Waugh will receive a fee of \$13,000 per month, plus \$520 per hour in excess of 25 hours per month, for a term of one year. In addition, the outstanding equity awards held by Dr. Waugh will continue to vest pursuant to their original terms while he is providing consulting services to the Company during the one year term.

A press release announcing the change is attached hereto as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Number	Description
99.1	Press Release dated July 2, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 2, 2015

Revance Therapeutics, Inc.

By: /s/ Lauren P. Silvernail
Lauren P. Silvernail
Executive Vice President, Corporate Development
and Chief Financial Officer

EXHIBIT INDEX

Number	Description
99.1	Press Release dated July 2, 2015.